Scaling a Personalized Portfolio: restor3d Completes Key Initiative Following Conformis Acquisition
restor3d Completes Acquisition of Conformis
Independent Proxy Advisory Firm ISS Recommends Conformis Stockholders Vote “FOR” the Pending Merger with restor3d
ConforMIS (CFMS) Reports Q2 Loss, Tops Revenue Estimates
Conformis Reports Second Quarter 2023 Financial Results
CONFORMIS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Conformis, Inc. - CFMS
Shareholder Alert: Ademi LLP investigates whether Conformis, Inc. has obtained a Fair Price in its transaction with restor3d
Shareholder Alert: Ademi LLP investigates whether Conformis, Inc. has obtained a Fair Price in its transaction with restor3d
CFMS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Conformis, Inc. Is Fair to Shareholders
Conformis stock nearly doubles in active trading after cash buyout deal with Restor3d
Conformis Announces Definitive Agreement to be Acquired by restor3d for a Purchase Price of $2.27 Per Share in Cash
ConforMIS (CFMS) Reports Q1 Loss, Tops Revenue Estimates
Conformis, Inc. (CFMS) Q1 2023 Earnings Call Transcript
Conformis Reports First Quarter 2023 Financial Results
Conformis, Inc. to Announce Financial Results for Its First Quarter on May 8, 2023
Conformis Launches Patient Awareness Campaign to Highlight the Benefits of Personalized Knee Replacement Procedures
ConforMIS (CFMS) Moves to Buy: Rationale Behind the Upgrade
Conformis, Inc. (CFMS) Q4 2022 Earnings Call Transcript
Conformis, Inc. Reports Fourth Quarter and Year End 2022 Financial Results
Conformis, Inc. to Participate in Upcoming Investor Conferences
Conformis, Inc., Bodycad Laboratories, Inc. and Bodycad USA Corp. Announce Settlement of Patent Litigation
Conformis Provides Business Update and Reports Preliminary Results for Fourth Quarter and Full-Year 2022
Conformis, Inc. to Announce Financial Results for Its Fourth Quarter and Full-Year 2022
Conformis, Inc. Regains Compliance with Nasdaq's Minimum Bid Price Rule
Conformis Announces First Procedure Performed Using New Actera™ Hip System
Conformis Announces Full Commercial Launch of Imprint™
Conformis, Inc. Announces Settlement of Medacta Patent Litigation
Conformis, Inc. (CFMS) Q3 2022 Earnings Call Transcript
ConforMIS (CFMS) Reports Q3 Loss, Misses Revenue Estimates
Conformis Reports Third Quarter 2022 Financial Results
Conformis, Inc. to Announce Financial Results for Its Third Quarter 2022
Conformis Actera™ Hip System Receives 510(k) Clearance from the U.S. Food and Drug Administration
Conformis, Inc. to Participate in the H.C. Wainwright & Co. 24th Annual Global Investment Conference
Conformis, Inc. (CFMS) CEO Mark Augusti on Q2 2022 Results - Earnings Call Transcript
ConforMIS (CFMS) Reports Q2 Loss, Tops Revenue Estimates
Conformis Reports Second Quarter 2022 Financial Results
Conformis Announces New Agreement with Vizient for Personalized Orthopedic Implants
Conformis, Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference
Conformis, Inc. to Release Second Quarter 2022 Financial Results on August 8, 2022
Conformis, Inc. to Participate in the H.C. Wainwright Global Investment Conference
Conformis, Inc. (CFMS) CEO Mark Augusti on Q1 2022 Results - Earnings Call Transcript
ConforMIS (CFMS) Reports Q1 Loss, Tops Revenue Estimates
Conformis Reports First Quarter 2022 Financial Results
Conformis, Inc. to Release First Quarter 2022 Financial Results on May 4, 2022
Conformis, Inc. Appoints Michael Fillion as Chief Operating Officer
Conformis Partners with Synchrony to Offer CareCredit Financial Services to Orthopedic Patients
Conformis, Inc. Appoints Denise Pedulla as Chief Legal Officer and Corporate Secretary
Gary Fischetti nominated to join Conformis' Board of Directors
Conformis' Q4 Miss Street View As Earnings Impacted By Surge In COVID-19 Cases
Conformis, Inc.'s (CFMS) CEO Mark Augusti on Q4 2021 Results - Earnings Call Transcript